-

Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a license agreement with LEXEO Therapeutics, Inc. (LEXEO), which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

The collaboration is focused on using [F-18]MK-6240 as a biomarker in LEXEO’s ongoing clinical study Protocol LX1001-01, an investigational gene therapy candidate for APOE4-associated Alzheimer’s disease.

“Cerveau is pleased to be working with LEXEO to better understand Tau PET’s utilization in supporting therapeutic trials,” said Rick Hiatt, Chief Executive Officer, Cerveau Technologies, Inc. “The collaboration with LEXEO is another important step forward in our strategy of expanding our international network of key academic and pharmaceutical industry collaborators in order to help fight against neurodegenerative diseases.”

About Cerveau Technologies, Inc.

Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.

Contacts

Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com

Industry:

Cerveau Technologies, Inc.

Release Summary
LEXEO - Cerveau
Release Versions
English

Contacts

Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com

More News From Cerveau Technologies, Inc.

Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, also previously referred to as MK-6240), a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle (NFT) pathology. In 2023, EB USA sold its subsidiary, C...

Enigma Biomedical USA awarded a grant from The Michael J. Fox Foundation for Discovery and Development of Novel α-Synuclein PET Imaging Biomarker

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA (EB USA) today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has awarded EB USA $2 million for the discovery and initial preclinical development of a novel α-synuclein Positron Emission Tomography (PET) Imaging biomarker. This funding is part of MJFF’s strategic research agenda focused on supporting objective tools to biologically measure and track the progression of Parkinson’s disease (PD) to improve clin...

Enigma Biomedical USA announces FDA Acceptance of New Drug Application for florquinitau F-18 (MK-6240), a Tau PET Alzheimer’s Disease radiodiagnostic

KNOXVILLE, Tenn. & BEDFORD, Mass.--(BUSINESS WIRE)--Enigma Biomedical USA (EB USA) today announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for MK-6240 (florquinitau F-18), their Tau Positron Emission Tomography (PET) Alzheimer’s disease radiodiaganostic. The FDA previously granted MK-6240 fast track status, which is a recognition of the potential to address an important unmet need. MK-6240 specifically targets a pathological form of tau called tau n...
Back to Newsroom